Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance – And What’s Next

• Tarsus Pharmaceuticals, Inc. reported past second-quarter 2026 results showing revenue of US$173.91 million versus US$102.66 million a year earlier, with net loss narrowing to US$18.55 million and loss per share from continuing operations improving to US$0.43.
• Alongside these results, the company raised its 2026 XDEMVY net product sales guidance to a higher US$685 million–US$705 million range, signaling management’s increased confidence in the product’s commercial trajectory.
• We’ll now examine how this upgraded XDEMVY sales guidance could reshape Tarsus’s investment narrative and its longer-term growth assumptions.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Tarsus Pharmaceuticals Investment Narrative Recap

To own Tarsus, you need to believe XDEMVY can keep growing in a relatively new category while the company steadily reins in losses and builds a broader portfolio. The raised 2026 XDEMVY sales guidance, coming alongside stronger top line and a slightly narrower net loss, supports the near term revenue story but does not remove key risks around single product dependence, high SG&A, and the need for durable physician and patient adoption.

The most relevant recent announcement is Tarsus increasing its 2026 XDEMVY net product sales guidance to US$685 million to US$705 million, directly tied to the second quarter results. This higher range reinforces XDEMVY’s central role in the thesis and elevates the importance of sustaining uptake and retreatment rates. It also sharpens the risk that any slowdown in prescriptions, pricing pressure, or competitive entry could have an outsized effect on both revenue and progress toward profitability.

Yet beneath the upgraded guidance, investors should still pay close attention to how Tarsus manages its high SG&A spend and dependence on a single drug…

Read the full narrative on Tarsus Pharmaceuticals (it’s free!)

Tarsus Pharmaceuticals’ narrative projects $1.1 billion revenue and $632.5 million earnings by 2029. This requires 28.3% yearly revenue growth and about a $680.8 million earnings increase from -$48.3 million today.

Uncover how Tarsus Pharmaceuticals’ forecasts yield a $94.11 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming about US$1.4 billion in revenue and roughly US$473 million in earnings by 2029, so this guidance lift may either reinforce that bullish view around stronger XDEMVY adoption or prompt a reset if risks like concentrated revenue from one product start to weigh more heavily in your own expectations.

Explore 4 other fair value estimates on Tarsus Pharmaceuticals – why the stock might be worth just $84.00!

Form Your Own Verdict

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

• A great starting point for your Tarsus Pharmaceuticals research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Tarsus Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Tarsus Pharmaceuticals’ overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com